Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer : A retrospective analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1613-7671
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer ; day:21 ; month:8 ; year:2018 ; pages:1-6
Wiener klinische Wochenschrift ; (21.8.2018), 1-6
- Creator
-
Asamer, Eva
- Contributor
-
Szkandera, Joanna
Gibiser, Paul
Lembeck, Anna Lena
Stojakovic, Tatjana
Kornprat, Peter
Lackner, Caroline
Winder, Thomas
Schlick, Konstantin
Stöger, Herbert
Gerger, Armin
Pichler, Martin
Stotz, Michael
SpringerLink (Online service)
- DOI
-
10.1007/s00508-018-1383-3
- URN
-
urn:nbn:de:101:1-2018092810062298799277
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:40 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Asamer, Eva
- Szkandera, Joanna
- Gibiser, Paul
- Lembeck, Anna Lena
- Stojakovic, Tatjana
- Kornprat, Peter
- Lackner, Caroline
- Winder, Thomas
- Schlick, Konstantin
- Stöger, Herbert
- Gerger, Armin
- Pichler, Martin
- Stotz, Michael
- SpringerLink (Online service)
Other Objects (12)
Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer: a retrospective analysis
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Best of ASCO 2022: bladder cancer
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Inflammation, phagocytosis and cancer: another step in the CD47 act
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer — the more specific, the better?
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients
Involvement of the long noncoding RNA NEAT1 in carcinogenesis
RNA-binding proteins as important regulators of long non-coding RNAs in cancer
Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer: a retrospective analysis
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Best of ASCO 2022: bladder cancer
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Inflammation, phagocytosis and cancer: another step in the CD47 act
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer — the more specific, the better?
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients
Involvement of the long noncoding RNA NEAT1 in carcinogenesis
RNA-binding proteins as important regulators of long non-coding RNAs in cancer
Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer: a retrospective analysis
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Best of ASCO 2022: bladder cancer
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Inflammation, phagocytosis and cancer: another step in the CD47 act
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer — the more specific, the better?
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients
Involvement of the long noncoding RNA NEAT1 in carcinogenesis